共 41 条
[1]
Ailani J(2021)The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice Headache 61 1021-1039
[2]
Burch RC(2017)Migraine prophylaxis and acute treatment patterns among commercially insured patients in the United States Headache 57 1399-1408
[3]
Robbins MS(2008)Medication compliance and persistence: terminology and definitions Value Health 11 44-47
[4]
Woolley JM(2013)Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II) Headache 53 644-655
[5]
Bonafede MM(2010)OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial Cephalalgia 30 804-814
[6]
Maiese BA(2021)Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study J Headache Pain 22 27-undefined
[7]
Lenz RA(2022)Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study (P10–2.004) Neurology 98 716-undefined
[8]
Cramer JA(undefined)undefined undefined undefined undefined-undefined
[9]
Roy A(undefined)undefined undefined undefined undefined-undefined
[10]
Burrell A(undefined)undefined undefined undefined undefined-undefined